BioSpace News Archive

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered into a new $25 million credit financing facility with Silicon Valley Bank (SVB).

Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the closing of a $40 million Series A financing.

Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the publication of preclinical data supporting the potential of VAX-24, its lead vaccine candidate, in the journal Vaccine

BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the U.S. Food and Drug Administration (FDA) has given the Company clearance to proceed to human trials for BICX104, an implantable naltrexone pellet for the treatment of Opioid Use Disorder (OUD).

Arcadia Biosciences, Inc. ® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional content of crops and food ingredients, today announced that it will release its financial and business results for the first quarter of 2021 after market close on May 17, 2021 .

Good Neighbor Pharmacy, AmerisourceBergen’s network of independent community pharmacies, launched a COVID-19 Vaccines Pharmacy Locator Tool on MyGNP.com, a web-based platform designed to conveniently connect individuals with their local community pharmacy to receive COVID-19 vaccines.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina (“COSIMA”) trial.

New in vivo data demonstrate the broad anti-inflammatory activity of KT-474 and its superiority compared to a clinically active small molecule IRAK4 kinase inhibitor in preclinical immune-inflammatory models KT-474 is in Phase 1 clinical development as a first-in-class oral IRAK4 degrader for the treatment of immune-inflammatory diseases, such as atopic dermatitis, hidradenitis suppurativa, rheumatoid arthritis, and potentially others

Potential First-in-Class Medicine Blocking TSLP, an Epithelial Cytokine Tezepelumab is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients

DiA Imaging Analysis Ltd. (DiA), a leading provider of AI-powered ultrasound analysis solutions today announced that it has partnered with SonoScape Medical Corporation (300633.SZ), a leading developer and manufacturer of ultrasound systems.